ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
68 070,02
0,51%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Immunome Inc (IMNM)

  7. Immunome Inc (IMNM) Actualités

IMNM

Immunome (IMNM)

Immunome Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:IMNM
DateHeureSourceTitreSymboleSociété
20/05/202414h00Business WireImmunome Announces Completion of Purchase of Assets from AtrecaNASDAQ:IMNMImmunome Inc
17/05/202423h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMNMImmunome Inc
17/05/202414h00Business WireImmunome Announces Promotion of Max Rosett to Chief Financial OfficerNASDAQ:IMNMImmunome Inc
14/05/202414h48Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMNMImmunome Inc
14/05/202414h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMNMImmunome Inc
14/05/202414h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNMImmunome Inc
14/05/202414h00Business WireImmunome Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IMNMImmunome Inc
08/05/202414h00Business WireImmunome to Present at 2024 Bank of America Healthcare ConferenceNASDAQ:IMNMImmunome Inc
02/05/202414h00Business WireImmunome Appoints Kinney Horn as Chief Business OfficerNASDAQ:IMNMImmunome Inc
25/04/202414h26Business WireImmunome Appoints Sandra M. Swain to Board of DirectorsNASDAQ:IMNMImmunome Inc
05/04/202414h00Business WireImmunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:IMNMImmunome Inc
28/03/202421h02Business WireImmunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired AssetsNASDAQ:IMNMImmunome Inc
26/03/202413h00Business WireImmunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From AyalaNASDAQ:IMNMImmunome Inc
07/03/202414h00Business WireImmunome to Participate in the Leerink Partners Global Biopharma ConferenceNASDAQ:IMNMImmunome Inc
01/03/202414h00Business WireImmunome to Participate in the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:IMNMImmunome Inc
22/02/202403h07Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMNMImmunome Inc
20/02/202414h15Business WireImmunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid TumorsNASDAQ:IMNMImmunome Inc
16/02/202422h05Business WireImmunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:IMNMImmunome Inc
14/02/202404h38Business WireImmunome Announces Pricing of Public Offering of Common StockNASDAQ:IMNMImmunome Inc
13/02/202422h05Business WireImmunome Announces Proposed Public Offering of Common StockNASDAQ:IMNMImmunome Inc
12/02/202420h10Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMNMImmunome Inc
05/02/202414h00Business WireImmunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:IMNMImmunome Inc
02/02/202422h04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IMNMImmunome Inc
08/01/202413h00Business WireImmunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology PlatformNASDAQ:IMNMImmunome Inc
04/01/202414h00Business WireImmunome Appoints Phil Roberts as Chief Technical OfficerNASDAQ:IMNMImmunome Inc
03/01/202414h00Business WireImmunome to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:IMNMImmunome Inc
02/01/202414h00Business WireImmunome Appoints Carol A. Schafer to Board of DirectorsNASDAQ:IMNMImmunome Inc
26/12/202314h30GlobeNewswire Inc.Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to ImmunomeNASDAQ:IMNMImmunome Inc
26/12/202314h30Business WireImmunome to Acquire Antibody-Related Assets and Materials from AtrecaNASDAQ:IMNMImmunome Inc
28/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IMNMImmunome Inc
 Showing the most relevant articles for your search:NASDAQ:IMNM

Dernières Valeurs Consultées

EU
BE0002770510
Region de Bruxelles Capi...
DBI
G86T
XUNZPPAU1CUSDINAV
AMEX
XOP
SPDR S&P Oil and Gas Exp...
ASX
2BE
Tubi
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés